PMID- 36174825
OWN - NLM
STAT- MEDLINE
DCOM- 20221216
LR  - 20221221
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 371
DP  - 2023 Jan 15
TI  - Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure 
      control and clinical outcomes for elderly patients with heart failure and 
      hypertension: A prospective cohort study.
PG  - 244-251
LID - S0167-5273(22)01400-0 [pii]
LID - 10.1016/j.ijcard.2022.09.050 [doi]
AB  - AIM: This study was conducted to investigate the safety and effectiveness of 
      sacubitril/valsartan (sac/val) for elderly patients with hypertension and heart 
      failure in the real-world setting. METHODS: Patients with established 
      hypertension complicated with structural or functional impairment of ventricular 
      fillings [New York Heart Association (NYHA) functional class II-IV)] were 
      enrolled. The effectiveness of sac/val in terms of BP reduction and improvement 
      in frailty and echocardiographic evaluation of cardiac function were examined 
      from baseline to 6-month administration. RESULTS: Overall, 241 patients were 
      treated with sac/val and 227 with renin angiotensin aldosterone system inhibitor 
      (RAASi) for hypertension control. There were significant difference in the degree 
      of systolic blood pressure reduction between two groups. Echocardiography showed 
      that sac/val significantly improved left ventricular ejection fraction [4.0% (95% 
      CI: 2.0-7.5) vs -1.0 (95% CI: -4.0-2.0), P = 0.001] during the follow-up visits. 
      Significant improvements in NYHA function class and FRAIL scores post sac/val 
      were observed after 3 and 6 month treatment. The rate of primary cardiovascular 
      composite outcome was higher in patients in the RAASi group (26.9%; 95% CI: 
      19.6-34.0) than in the sac/val group (22.0%; 95% CI: 16.7-27.3). CONCLUSIONS: 
      Sac/val may be useful not only for reducing BP, but also for improving the 
      structural and functional parameters of echocardiography, eventually resulting in 
      a significant improvement of the overall symptomatic status, a significant 
      reduction in NYHA class, and functional improvement.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Li, Xiaoye
AU  - Li X
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China.
FAU - Zuo, Chengchun
AU  - Zuo C
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China.
FAU - Chen, Can
AU  - Chen C
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China.
FAU - Tian, Dan
AU  - Tian D
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China.
FAU - Li, Jing
AU  - Li J
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China.
FAU - Fan, Linlin
AU  - Fan L
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China.
FAU - Li, Xiaoyu
AU  - Li X
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China.. Electronic address: li.xiaoyu@zs-hospital.sh.cn.
FAU - Lv, Qianzhou
AU  - Lv Q
AD  - Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      China.. Electronic address: 13916088938@163.com.
LA  - eng
PT  - Journal Article
DEP - 20220927
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Tetrazoles)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Aminobutyrates)
RN  - 80M03YXJ7I (Valsartan)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
SB  - IM
MH  - Humans
MH  - Aged
MH  - Stroke Volume/physiology
MH  - Blood Pressure
MH  - Prospective Studies
MH  - Tetrazoles/adverse effects
MH  - Angiotensin Receptor Antagonists/adverse effects
MH  - Ventricular Function, Left/physiology
MH  - Aminobutyrates/adverse effects
MH  - Valsartan/therapeutic use
MH  - *Heart Failure/diagnostic imaging/drug therapy/chemically induced
MH  - Biphenyl Compounds/therapeutic use
MH  - Drug Combinations
MH  - *Hypertension/diagnosis/drug therapy/chemically induced
MH  - *Hypotension/drug therapy
OTO - NOTNLM
OT  - Effectiveness and safety
OT  - Elderly
OT  - Heart failure
OT  - Hypertension
OT  - Sacubitril/valsartan
EDAT- 2022/09/30 06:00
MHDA- 2022/12/15 06:00
CRDT- 2022/09/29 19:35
PHST- 2022/04/01 00:00 [received]
PHST- 2022/09/20 00:00 [revised]
PHST- 2022/09/21 00:00 [accepted]
PHST- 2022/09/30 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
PHST- 2022/09/29 19:35 [entrez]
AID - S0167-5273(22)01400-0 [pii]
AID - 10.1016/j.ijcard.2022.09.050 [doi]
PST - ppublish
SO  - Int J Cardiol. 2023 Jan 15;371:244-251. doi: 10.1016/j.ijcard.2022.09.050. Epub 
      2022 Sep 27.